5.27
1.76%
-0.09
Voyager Therapeutics Inc stock is traded at $5.27, with a volume of 117.23K.
It is down -1.76% in the last 24 hours and down -31.26% over the past month.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
See More
Previous Close:
$5.36
Open:
$5.35
24h Volume:
117.23K
Relative Volume:
0.21
Market Cap:
$292.79M
Revenue:
$163.78M
Net Income/Loss:
$25.88M
P/E Ratio:
2.3216
EPS:
2.27
Net Cash Flow:
$-28.66M
1W Performance:
-15.34%
1M Performance:
-31.26%
6M Performance:
-37.61%
1Y Performance:
-21.52%
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
VYGR | 5.27 | 292.79M | 163.78M | 25.88M | -28.66M | 2.27 |
VRTX | 446.95 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 742.11 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 588.63 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 250.00 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 103.98 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-10-23 | Initiated | Truist | Buy |
Mar-10-23 | Initiated | Oppenheimer | Outperform |
Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Mar-19-20 | Initiated | The Benchmark Company | Buy |
Feb-06-20 | Initiated | Oppenheimer | Outperform |
Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-10-18 | Resumed | BTIG Research | Buy |
Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-04-18 | Initiated | H.C. Wainwright | Buy |
Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
Feb-02-18 | Initiated | Morgan Stanley | Overweight |
Nov-28-17 | Resumed | Piper Jaffray | Overweight |
Oct-31-17 | Initiated | Robert W. Baird | Outperform |
Oct-27-17 | Initiated | Canaccord Genuity | Buy |
Oct-23-17 | Reiterated | Stifel | Buy |
Oct-12-17 | Initiated | Raymond James | Outperform |
Aug-17-17 | Initiated | Evercore ISI | Outperform |
Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease - GlobeNewswire
Voyager's New Alzheimer's Gene Therapy Shows 73% Tau Reduction in Key Study | VYGR Stock News - StockTitan
Voyager Therapeutics’ TRACER Platform Targets CNS Market: Here’s Why I’m Neutral (VYGR) - Seeking Alpha
StockNews.com Upgrades Voyager Therapeutics (NASDAQ:VYGR) to "Buy" - MarketBeat
FY2024 Earnings Forecast for VYGR Issued By HC Wainwright - MarketBeat
Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at Canaccord Genuity Group - Defense World
Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright - Defense World
When the Price of (VYGR) Talks, People Listen - Stock Traders Daily
Voyager Therapeutics stock hits 52-week low at $5.71 - Investing.com India
EcoR1 Capital, LLC Increases Stake in Voyager Therapeutics Inc - GuruFocus.com
Leerink Partnrs Has Negative Outlook of VYGR FY2024 Earnings - MarketBeat
Voyager Therapeutics' (VYGR) Buy Rating Reiterated at Canaccord Genuity Group - MarketBeat
Voyager Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)? - Yahoo Finance
Earnings call: Voyager Therapeutics focuses on neurological therapies By Investing.com - Investing.com Canada
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2024 Earnings Call Transcript - Insider Monkey
Voyager Therapeutics: Q3 Earnings Snapshot - Darien Times
Voyager Therapeutics Inc earnings beat by $0.29, revenue topped estimates - Investing.com India
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance
Voyager Therapeutics Reports Strong Q3 2024 Progress - TipRanks
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings: Revenue Soars to $24.63M, EPS Loss of $0.16 Beats Estimates - GuruFocus.com
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Voyager Reports Third Quarter 2024 Financial and Operating Results - GlobeNewswire
Voyager Therapeutics Revenue Soars 435% in Q3, Secures $15M Novartis Deal | VYGR Stock News - StockTitan
Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Voyager Therapeutics (NASDAQ:VYGR) Cut to Hold at StockNews.com - MarketBeat
Gene Therapy Market to Grow by USD 6.74 Billion from 2024-2028, as Rise in Special Drug Designations Drives Demand with AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Voyager Therapeutics (VYGR) to Release Quarterly Earnings on Tuesday - MarketBeat
Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences - The Manila Times
Voyager Therapeutics to Present at 4 Major Healthcare Investor Conferences in November | VYGR Stock News - StockTitan
Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - GlobeNewswire
VYGRVoyager Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Voyager Therapeutics (VYGR) to Report Q3 2024 Earnings on November 12 | VYGR Stock News - StockTitan
Learn to Evaluate (VYGR) using the Charts - Stock Traders Daily
Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength? - MSN
Voyager Therapeutics (NASDAQ:VYGR) Rating Increased to Buy at StockNews.com - MarketBeat
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Canada Finance
Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) PT at $17.43 - MarketBeat
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of “Buy” from Analysts - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Lowered by StockNews.com - Defense World
StockNews.com Lowers Voyager Therapeutics (NASDAQ:VYGR) to Hold - MarketBeat
How to Take Advantage of moves in (VYGR) - Stock Traders Daily
HC Wainwright Reaffirms Buy Rating for Voyager Therapeutics (NASDAQ:VYGR) - MarketBeat
Viral Vectors-Based Gene Therapy for Non-Human Primates Market - openPR
Equities Analysts Offer Predictions for VYGR Q3 Earnings - MarketBeat
Voyager Therapeutics (NASDAQ:VYGR) Rating Increased to Strong-Buy at Leerink Partnrs - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to "Strong-Buy" by Leerink Partnrs - MarketBeat
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):